N/A N=30 Triple-blind Health Services Research

The Various Effects of Gaseous Albuterol on Serum Lactate

Asthma

Bottom Line

View on ClinicalTrials.gov: NCT02073747 ↗

Enrolled (actual)

Serious AEs

0.0%

Results posted

Aug 2017

Primary outcome: Primary: Number of Subjects With a Change From Baseline Serum Lactate Following a One Hour Albuterol Nebulizer Treatment. — -0.15; 0.77 mmol/L

Study Design & Population

Study type: Interventional
Phase: N/A
Interventions: Normal Saline (Drug); Albuterol (Drug)
Age: Adult, Older Adult · 18+ yrs
Sex: All
Sponsor: University Medical Center of Southern Nevada
Primary completion: Jul 2015

Outcome Measures

Outcome	Result	p-value
PRIMARY Number of Subjects With a Change From Baseline Serum Lactate Following a One Hour Albuterol Nebulizer Treatment.	-0.15; 0.77	—

Summary

Empirical data from physician observation indicates an increase in serum lactate in acute asthmatic patients being treated with inhaled albuterol therapy. It is not clear if this increased serum lactate is in response to a physiological response to the asthmatic process or from the albuterol treatment. This study is designed to determine if administration of inhaled albuterol increases serum lactate in healthy subjects.

Eligibility Criteria

Inclusion Criteria

18 years or older

Exclusion Criteria

Pregnant
Prisoner
beta agonist allergy
hypokalemia
taking furosemide, insulin, thiazide diuretics, metformin or acetazolamide
coronary artery disease
hyperthyroidism
abnormal heart rhythm
baseline serum lactate level >2.2 mmol/L
baseline heart rate > 120

View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT02073747). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.